These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 33728583

  • 21. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
    Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, Kantor R, Hsu DY, Silverberg JI.
    Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
    [Abstract] [Full Text] [Related]

  • 22. Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis.
    Fowler J, Sugarman J, Sher L, Zang C, Werth JL, Myers DE, Graham D, Marfo AA, Takiya L.
    Dermatol Ther (Heidelb); 2023 Apr; 13(4):951-960. PubMed ID: 36811773
    [Abstract] [Full Text] [Related]

  • 23. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.
    Armstrong AW, Alexis AF, Blauvelt A, Silverberg JI, Feeney C, Levenberg M, Chan G, Zhang F, Fostvedt L.
    Dermatol Ther (Heidelb); 2024 Jul; 14(7):1849-1861. PubMed ID: 38896380
    [Abstract] [Full Text] [Related]

  • 24. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study.
    Leshem YA, Hajar T, Hanifin JM, Simpson EL.
    Br J Dermatol; 2015 Jul; 172(5):1353-7. PubMed ID: 25580670
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
    Tom WL, Van Syoc M, Chanda S, Zane LT.
    Pediatr Dermatol; 2016 Jul; 33(2):150-9. PubMed ID: 26777394
    [Abstract] [Full Text] [Related]

  • 26. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
    Alexis A, de Bruin-Weller M, Weidinger S, Soong W, Barbarot S, Ionita I, Zhang F, Valdez H, Clibborn C, Yin N.
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
    [Abstract] [Full Text] [Related]

  • 27. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
    Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S, Van Syoc M, Hebert AA.
    Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
    Callender VD, Alexis AF, Stein Gold LF, Lebwohl MG, Paller AS, Desai SR, Tan H, Ports WC, Zielinski MA, Tallman AM.
    Am J Clin Dermatol; 2019 Oct; 20(5):711-723. PubMed ID: 31264114
    [Abstract] [Full Text] [Related]

  • 29. Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.
    Gooderham MJ, Girolomoni G, Moore JO, Silverberg JI, Bissonnette R, Forman S, Peeva E, Biswas P, Valdez H, Chan G.
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2077-2085. PubMed ID: 35933552
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson EL.
    JAMA Dermatol; 2020 Apr 01; 156(4):411-420. PubMed ID: 32101256
    [Abstract] [Full Text] [Related]

  • 31. IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
    Paller AS, Tan JKL, Bagel J, Rossi AB, Shumel B, Zhang H, Abramova A.
    Br J Dermatol; 2022 Mar 01; 186(3):496-507. PubMed ID: 34726270
    [Abstract] [Full Text] [Related]

  • 32. Crisaborole: A Novel Nonsteroidal Topical Treatment for Atopic Dermatitis.
    McDowell L, Olin B.
    J Pharm Technol; 2019 Aug 01; 35(4):172-178. PubMed ID: 34861031
    [Abstract] [Full Text] [Related]

  • 33. Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.
    Penton H, Jayade S, Selveindran S, Heisen M, Piketty C, Ulianov L, Jabbar-Lopez ZK, Silverberg JI, Puelles J.
    Dermatol Ther (Heidelb); 2023 Nov 01; 13(11):2549-2571. PubMed ID: 37747670
    [Abstract] [Full Text] [Related]

  • 34. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
    Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M.
    J Eur Acad Dermatol Venereol; 2021 Sep 01; 35(9):1797-1810. PubMed ID: 33991374
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R.
    Lancet; 2020 Jul 25; 396(10246):255-266. PubMed ID: 32711801
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
    Lin YK, Chang SH, Yang CY, See LC, Lee BH, Shih IH.
    J Ethnopharmacol; 2020 Mar 25; 250():112477. PubMed ID: 31838180
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E.
    JAMA Dermatol; 2019 Dec 01; 155(12):1371-1379. PubMed ID: 31577341
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, Rojo R.
    JAMA Dermatol; 2020 Aug 01; 156(8):863-873. PubMed ID: 32492087
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    Silverberg JI, Kirsner RS, Margolis DJ, Tharp M, Myers DE, Annis K, Graham D, Zang C, Vlahos BL, Sanders P.
    J Am Acad Dermatol; 2024 May 01; 90(5):945-952. PubMed ID: 38340127
    [Abstract] [Full Text] [Related]

  • 40. Mild to moderate atopic dermatitis severity can be reliably assessed using smartphone-photographs taken by the patient at home: A validation study.
    Ali Z, Chiriac A, Bjerre-Christensen T, Isberg AP, Dahiya P, Manole I, Dutei AM, Deaconescu I, Serban A, Suru A, Agner T, Kamstrup MR, Togsverd-Bo K, Zibert JR, Thomsen SF, Andersen AD.
    Skin Res Technol; 2022 Mar 01; 28(2):336-341. PubMed ID: 35020960
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.